Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-04457845
PF-04457845, FAAH inhibitor · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| PF-04457845 followed by placebo | EXPERIMENTAL | - |
| Placebo followed by PF-04457845 | EXPERIMENTAL | - |
| Naproxen followed by placebo | ACTIVE_COMPARATOR | - |
| Placebo followed by Naproxen | ACTIVE_COMPARATOR | - |
| Healthy adult volunteers | EXPERIMENTAL | Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex |
| Cohort 1 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days. |
| Cohort 2 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 1mg per day for 14 days. |
| Cohort 3 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 4mg per day for 14 days. |
| Cohort 4 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 8mg per day for 14 days. |
| Name | Type | Description |
|---|---|---|
| PF-04457845 | DRUG | PF-04457845 4 mg tablet once daily / matched placebo |
| Naproxen | DRUG | Naproxen 500 mg tablet twice daily / matched placebo |
| PF-04457845, FAAH inhibitor | DRUG | Oral solution of 0.5mg given once daily for 14 days. |
Inclusion Criteria: * Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray * Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study) * Subjects can be mal...
Top 5 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 3 | PHASE3 | Eloralintide and Tirzepatide, Orforglipron, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
PF-04457845 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for the treatment of pain. It has been studied in acute pain and in osteoarthritis of the knee, and it is also known as PF-04457845. It is a clinical-stage candidate that has not been approved for any indication.
PF-04457845 has been studied for the treatment of pain, including acute pain and osteoarthritis of the knee. Clinical testing has also been conducted in healthy volunteers to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. It is an investigational agent and is not approved for use in any indication.
PF-04457845 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical trials evaluating the compound in healthy volunteers and in patients with osteoarthritis of the knee. The drug remains an investigational asset in Pfizer's pain research portfolio.
PF-04457845 is in clinical development, with Phase 1 studies completed in healthy volunteers and a Phase 2 study completed in patients with osteoarthritis of the knee. It is an investigational drug and has not been approved by the FDA or any other regulatory authority for commercial use.
PF-04457845 has been evaluated in completed trials including NCT00981357, a Phase 2 study in osteoarthritis of the knee conducted in the United States, Canada, and Sweden, and two Phase 1 studies, NCT00918164 and NCT00836082, in healthy volunteers in Singapore. No trials of PF-04457845 are currently active.